{"filing":{"accession_number":"0001193125-26-265879","cik":"0001829802","ticker":"SNSE","company_name":"Sensei Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"d142513d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526265879/d142513d8k.htm"},"events":[{"id":5666,"run_id":4968,"accession_number":"0001193125-26-265879","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stockholders approved six proposals at the Annual Meeting on June 10, 2026, including election of directors, ratification of auditors, approval of a Series B convertible preferred stock issuance that triggers a change of control under Nasdaq rules, authorization of additional common shares, and approval of equity compensation plans.","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5894,"accession_number":"0001193125-26-265879","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the annual meeting on June 10, 2026. These are compensatory arrangements for directors and officers involving equity grants and employee stock purchase rights. The filing details the share reserves, automatic annual increases, and references the full plan documents, which is characteristic of exec_compensation disclosures under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:22:23.195650+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5895,"accession_number":"0001193125-26-265879","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 12.5 million to 300 million—a 24-fold increase. While this is a structural/governance change rather than a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, etc.), the dramatic expansion of authorized shares is material to investors as it signals potential for significant future dilution and may indicate preparation for capital raises, acquisitions, or equity-based compensation. This does not fit neatly into the provided categories and is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:22:23.195650+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5896,"accession_number":"0001193125-26-265879","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of an Annual Meeting of stockholders where six proposals were voted on and approved, including election of directors, ratification of auditors, approval of Series B convertible preferred stock issuance (which triggers a change of control under Nasdaq rules), authorization of additional common shares, and approval of equity compensation plans. The disclosure of shareholder vote results is the core purpose of Item 5.07, and the approval of the convertible preferred stock issuance and change of control is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:22:23.195650+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5894,"accession_number":"0001193125-26-265879","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of the 2026 Equity Incentive Plan and 2026 Employee Stock Purchase Plan at the annual meeting on June 10, 2026. These are compensatory arrangements for directors and officers involving equity grants and employee stock purchase rights. The filing details the share reserves, automatic annual increases, and references the full plan documents, which is characteristic of exec_compensation disclosures under Item 5.02(e).","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:22:23.195650+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-10"},{"id":5895,"accession_number":"0001193125-26-265879","item_number":"5.03","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The filing discloses a stockholder-approved amendment to the Certificate of Incorporation increasing authorized common shares from 12.5 million to 300 million—a 24-fold increase. While this is a structural/governance change rather than a discrete event type in the taxonomy (not earnings, M\u0026A, litigation, etc.), the dramatic expansion of authorized shares is material to investors as it signals potential for significant future dilution and may indicate preparation for capital raises, acquisitions, or equity-based compensation. This does not fit neatly into the provided categories and is best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:22:23.195650+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-10"},{"id":5896,"accession_number":"0001193125-26-265879","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 discloses the results of an Annual Meeting of stockholders where six proposals were voted on and approved, including election of directors, ratification of auditors, approval of Series B convertible preferred stock issuance (which triggers a change of control under Nasdaq rules), authorization of additional common shares, and approval of equity compensation plans. The disclosure of shareholder vote results is the core purpose of Item 5.07, and the approval of the convertible preferred stock issuance and change of control is material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:22:23.195650+00:00","company_name":"Sensei Biotherapeutics, Inc.","ticker":"SNSE","filing_date":"2026-06-10"}]}